Results:
Among the 147 patients who reached 24M of dulaglutide treatment in our previous study,11 we selected a cohort of those had reached 36M with an active prescription of dulaglutide. 52 of those were excluded because they did not meet the inclusion criteria. Of the 95 initial patients, we recorded eight drop-outs due to several causes (8.42%): (1) four due to change of GLP-1 RA; (2) one death; (3) gastrointestinal side effects in one and (4) two for unspecified causes.